Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AstraZeneca Buys Back 318283 Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 12:23pm CEST

AstraZeneca PLC (>> AstraZeneca plc) said Monday it has purchased 318,283 ordinary shares on April 27 at a price of 2666 pence per share for cancellation.

-Shares at 1005 GMT up 1%, at 2704 pence, valuing the company at GBP34 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : AstraZeneca plc
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.57% 598.4 Delayed Quote.5.86%
ASTRAZENECA -0.18% 4955.5 Delayed Quote.-3.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
04/19RESEARCHERS AT ASTRAZENECA HAVE REPO : ...
AQ
04/19ASTRAZENECA : Study Results from AstraZeneca Provide New Insights into Antineopl..
AQ
04/19ASTRAZENECA : Research from AstraZeneca Reveals New Findings on Pharmacokinetics..
AQ
04/19IONIS PHARMACEUTICALS : and AstraZeneca Advance New Drug for NASH
AQ
04/19MERCK AND : AstraZeneca and Merck - Updated Overall Survival Data for LYNPARZA i..
AQ
04/19ASTRAZENECA : to invest $90 million in India over next 5 years
AQ
04/19ASTRAZENECA : Cancer Drug Tagrisso Approved by FDA As First-Line Treatment
DJ
04/19ASTRAZENECA : FDA approves Tagrisso for 1st-line use in NSCLC
AQ
04/19ASTRAZENECA : US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated no..
PU
04/18Experts query case for GlaxoSmithKline's new 3-in-1 lung drug
RE
More news
News from SeekingAlpha
04/193 THINGS IN BIOTECH, APRIL 18 : Bristol Plows Ahead, Celldex Flops, Alkermes Get.. 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/17Evelo Biosciences Files For U.S. IPO 
04/172 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025 
04/16G1 Therapeutics initiates Phase 1b/2 clinical trial of G1T38 in combination w.. 
Financials ($)
Sales 2018 22 568 M
EBIT 2018 5 551 M
Net income 2018 1 898 M
Debt 2018 14 767 M
Yield 2018 3,96%
P/E ratio 2018 38,31
P/E ratio 2019 29,29
EV / Sales 2018 4,63x
EV / Sales 2019 4,39x
Capitalization 89 830 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 75,6 $
Spread / Average Target 7,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-3.06%89 830
JOHNSON & JOHNSON-6.57%342 627
PFIZER0.30%217 064
NOVARTIS-4.37%213 465
ROCHE HOLDING LTD.-12.15%193 887
MERCK AND COMPANY4.71%158 813